ArticleThe American journal of pathology2023
The TNF
Abstract read
In one paragraph
Article in The American journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.Inflammatory bowel diseases · 2026Article
- Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria.Aging cell · 2025Article
- The functional role of the extracellular matrix in inflammatory bowel disease associated gut fibrosis.Matrix biology : journal of the International Society for Matrix Biology · 2025Review
- Different fibroblast subtypes propel spatially defined ileal inflammation through TNFR1 signalling in murine ileitis.Nature communications · 2025Article
- Muscular hyperplasia in Crohn's disease strictures: through thick and thin.American journal of physiology. Cell physiology · 2024Review
- Authors' Reply.The American journal of pathology · 2024Article
- Review
Corrections and comments
- Commented on by
- Update ofThe TNF2023
Authors and funding
14 authors.
Calen A SteinerDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado. Electronic address: calen.steiner@cuanschutz.edu.
Samuel D KochDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.
Tamara EvanoffDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.
Nichole WelchDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.
Rachael KosteleckyDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.
Rosemary CallahanDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.
Emily M MurphyDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program and Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, Colorado.
Tom T NguyenMucosal Inflammation Program and Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, Colorado.
Caroline H T HallMucosal Inflammation Program and Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, Colorado.
Sizhao LuDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Edwin F de ZoetenMucosal Inflammation Program and Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, Colorado.
Mary C M Weiser-EvansDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Consortium for Fibrosis Research and Translation, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado; Cardiovascular Pulmonary Research Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Ian M CartwrightDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado.
Sean P ColganDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado.
Funding
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1MColorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0MROLE OF EPITHELIA IN ISCHEMIA/REPERFUSION INJURYR01DK050189 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2000 to 2024
$5.0MMechanisms of Adenosine ProtectionR01DK095491 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Sean P Colgan · 2012 to 2026
$4.9MMetabolic Regulation of Inflammation by Microbial SCFAR01DK104713 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Sean P Colgan · 2015 to 2026
$4.7MHypoxia, HIF, and Mucosal InflammationR37DK050189 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2010 to 2019
$4.1MmicroRNA-dependent regulation of intestinal T-cells²R01DK111856 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DE ZOETEN, EDWIN FULCO · 2018 to 2022
$1.7MMETABOLIC CONTROL OF EPITHELIAL AUTOPHAGY DURING INFLAMMATIONR01DK103712 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2015 to 2019
$1.7MMicrobial-derived purines in intestinal homeostasisF32DK122741 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LEE, JOSEPH SCOTT · 2019 to 2021
$140kEPITHELIA AND ISCHEMIA/REPERFUSION INJURYR29DK050189 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI COLGAN, SEAN P · 1995 to 1999
–STRUCTURAL AND MECHANISTIC STUDY OF SIROHEME SYNTHASEF32DK009549 · NIDDK · UNIVERSITY OF YORK · PI SCHUBERT, HEIDI L · 1996 to 1998
–Control of Inflammatory Acidity in Mucosal InflammationIK2BX005710 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI Ian Michael Cartwright · 2022 to 2026
–BLRD VA I01 BX002182BLRD VA IK2 BX005710BLRD VA IK6 BX006475NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR002535NIDDK NIH HHS F32 DK009549NIDDK NIH HHS F32 DK122741NIDDK NIH HHS R01 DK050189NIDDK NIH HHS R01 DK095491NIDDK NIH HHS R01 DK103712NIDDK NIH HHS R01 DK104713NIDDK NIH HHS R01 DK111856NIDDK NIH HHS R29 DK050189NIDDK NIH HHS R37 DK050189
Abstract
Crohn disease (CD) is a highly morbid chronic inflammatory disease. Although many patients with CD also develop fibrostenosing complications, there are no medical therapies for intestinal fibrosis. This is due, in part, to a lack of high-fidelity biomimetic models to enhance understanding and drug development, which highlights the need for developing in vivo models of inflammatory bowel disease-related intestinal fibrosis. This study investigates whether the TNF
Indexed as
Crohn DiseaseIntestinesAnimalsFibrosisIleumInflammationMice
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.